The Potential of Cannabidiol for Acute Respiratory Distress Syndrome in Covid-19 Publisher Pubmed



Azimi S¹ ; Saghafi F² ; Mohammadi MH³ ; Moghimi MH⁴ ; Akhavan SA⁴ ; Khataminia M⁵ ; Shirvani M⁶ ; Sohrevardi SM² ; Jamialahmadi T⁷ ; Sahebnasagh A⁸ ; Sahebkar A^{7, 9}
Source: Current Pharmaceutical Design Published:2023

Abstract

COVID-19 disease manifests itself in a wide range of signs and symptoms, beginning with mild symptoms, such as fever, cough, and dyspnea, progressing to acute respiratory distress syndrome (ARDS) and death in some cases. The cytokine storm, or an excess of cytokines released locally, is assumed to be the pri-mary cause of ARDS and mortality in COVID-19 patients. To enhance the survival rate of COVID-19 pa-tients, early management of the cytokine storm with immunomodulators is crucial. Although the effectiveness of some immunosuppressants, such as corticosteroids and tocilizumab, has been studied in clinical trials, the administration of these drugs should be exercised cautiously. Cannabidiol (CBD) is a non-psychotropic phyto-cannabinoid from Cannabis sativa extracts with anti-inflammatory properties. This review is intended to dis-cuss the possible utility of CBD for the management of COVID-19 patients, particularly those with ARDS. © 2023 Bentham Science Publishers.